Nomura Instinet positive on Dr. Rodino-Klapac joining Sarepta. Nomura Instinet analyst Christopher Marai views the appointment of Dr. Rodino-Klapac as Sarepta Therapeutics’ Vice President of a newly created gene-therapy unit positively. The news further indicates that Sarepta is broadly expanding its gene therapy program in neuromuscular diseases, Marai tells investors in a research note. He reiterates a Buy rating on the shares with a $131 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.